All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-02-24.
From the record
Insulet Corporation's filings since 2017 show 2 warning events: an auditor change (8-K item 4.01, 2 times, the latest 2026-02-24) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+25.1% a year over 10 filed years; profitable in 8 of 10.
From the record
Insulet Corporation's 10 filed years say what it did: revenue went from $231 million in fiscal 2014 to $2.7 billion in fiscal 2025, up 25.1% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 8 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 0.9% a year. 5% of cash flow returned. Insiders: 2 sales, 6 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Insulet Corporation's diluted share count grew about 0.9% a year, and dividends and buybacks returned about 5% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales and 6 purchases of their own stock on the open market in the year to 2026-10-05, buying about $3 million (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 16%: 16¢ of profit per shareholder dollar. Leverage 53%: owes 53¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Insulet Corporation earned about 16 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 61 cents per dollar of everything the company owns. Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count shrank 2.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 19% of 109 in its family; net margin 9.1%.
From the record
Insulet Corporation's standing among 109 graded names in its industry family: revenue of $2.7 billion in fiscal 2025 ranks in the top 12% by size; a net margin of 9.1% ranks in the top 19%; revenue growth of 27.5% a year over the last 3 filed years ranks in the top 27% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 27% of 91 in its family for leadership; chief executive since 2025.
From the record
Insulet Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Mcevoy, Ashley (President and CEO, as filed), filing under that title since 2025-05-02, 1.5 years (bottom 29% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 4.2 years (bottom 27%); 15 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (bottom 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 41% of 104 in its family for room to expand.
From the record
Insulet Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $716 million against debt of $931 million leaves -6.7% of its assets as net cash, bottom 31% of its family; cash from operations less capital spending is 13.9% of revenue (top 18%); a gross margin of 71.6% (top 27%); research spending of 11.1% of revenue (bottom 48%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 25% of 105 in its family for growth drivers.
From the record
Insulet Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 27.5% a year over the last three filed years against 25.1% over all 10, speeding up (top 26% of its family); the newest year grew 30.7% (top 23%); research spending grew 18.7% a year (top 25%); capital spending grew 15.9% a year (top 27%) (its annual reports). Insulet Corporation reported 3 product lines in fiscal 2025: U.S.Omnipod at $1.9 billion (71%), International Omnipod at $754 million (28%), Drug Delivery at $34 million (1%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 49% of 88 in its family for expectations against reality.
From the record
Insulet Corporation's newest year against its own record: revenue of $2.7 billion in fiscal 2025 came in 3.8% above the $2.6 billion its prior three years' pace pointed to (top 28% of its family); net income of $247 million against a prior three-year average of $210 million (top 48%); a net margin of 9.1% against 10.9% before (bottom 23%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made